Roche Holding’s Tecentriq immunotherapy, in combination with Avastin and chemotherapy, won U.S. FDA approval as a first-line treatment for a type of lung cancer.
The approval was based on results from a late-stage study, which showed the Tecentriq regimen helped patients with metastatic non-squamous non-small cell lung cancer (NSCLC) live significantly longer, compared with Avastin and chemotherapy.
Tecentriq is already approved in the U.S. to treat certain types of lung cancers, as well as a type of bladder and urinary tract cancer.
The newly-approved regimen—containing Tecentriq, Roche's older blockbuster, Avastin and chemotherapy— will now face up against rival Merck’s Keytruda.
[javascriptSnippet]
